

ENCISION INC
Form 10-Q
February 13, 2009
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

- x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended December 31, 2008

OR

- o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission file number 0-28604

ENCISION INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: ENCISION INC - Form 10-Q

Colorado

(State or other jurisdiction of incorporation or organization)

84-1162056

(I.R.S. Employer Identification No.)

6797 Winchester Circle

Boulder, Colorado 80301

(Address of principal executive offices)

(303) 444-2600

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

Common Stock, no par value
(Class)

6,455,100 Shares
(outstanding at January 31, 2009)

Transitional Small Business Disclosure Format

Yes o No x

Table of Contents

ENCISION INC.

FORM 10-Q

For the Quarter Ended December 31, 2008

INDEX

		Page Number
<u>PART I.</u>	<u>FINANCIAL INFORMATION</u>	
<u>ITEM 1</u>	<u>– Condensed Interim Financial Statements:</u>	
	<u>– Condensed Balance Sheets as of December 31, 2008 and March 31, 2008</u>	3
	<u>– Condensed Statements of Operations for the Three Months Ended December 31, 2008 and 2007</u>	4
	<u>– Condensed Statements of Operations for the Nine Months Ended December 31, 2008 and 2007</u>	5
	<u>– Condensed Statements of Cash Flows for the Nine Months Ended December 31, 2008 and 2007</u>	6
	<u>– Notes to Condensed Interim Financial Statements</u>	7
<u>ITEM 2</u>	<u>– Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	11
<u>ITEM 4</u>	<u>– Controls and Procedures</u>	16
<u>PART II.</u>	<u>OTHER INFORMATION</u>	
<u>ITEM 6</u>	<u>– Exhibits</u>	17
<u>SIGNATURE</u>		18

Table of Contents**PART I** **FINANCIAL INFORMATION****ITEM 1** – **CONDENSED INTERIM FINANCIAL STATEMENTS****Encision Inc.****Condensed Balance Sheets****(unaudited)**

	December 31, 2008	March 31, 2008
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 72,380	\$ 70,995
Accounts receivable, net of allowance for doubtful accounts of \$14,000 at December 31, 2008 and \$15,000 at March 31, 2008	1,432,854	1,452,770
Inventories, net of reserve for obsolescence of \$45,000 at December 31, 2008 and \$65,000 at March 31, 2008	2,098,137	2,270,953
Prepaid expenses	101,569	99,025
Total current assets	3,704,940	3,893,743
Equipment, at cost:		
Furniture, fixtures and equipment	1,917,515	1,776,823
Customer-site equipment	688,504	644,946
Accumulated depreciation	(1,795,277)	(1,623,432)
Equipment, net	810,742	798,337
Patents, net of accumulated amortization of \$125,909 at December 31, 2008 and \$116,652 at March 31, 2008	218,481	199,246
Other assets	31,666	53,149
TOTAL ASSETS	\$ 4,765,829	\$ 4,944,475
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 672,964	\$ 536,755
Accrued compensation	293,454	391,889
Other accrued liabilities	392,072	481,106
Line of credit	198,942	
Total current liabilities	1,557,432	1,409,750
Long-term debt		606,000
Commitments and contingencies (Note 3)		
Shareholders' equity:		
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding		
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 6,455,100 and 6,447,100 shares issued and outstanding at December 31, 2008 and March 31, 2008, respectively	19,523,110	19,387,331
Accumulated (deficit)	(16,314,713)	(16,458,606)
Total shareholders' equity	3,208,397	2,928,725
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 4,765,829	\$ 4,944,475

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents**Encision Inc.****Condensed Statements of Operations****(Unaudited)**

Three Months Ended	December 31, 2008	December 31, 2007
NET SALES	\$ 3,270,854	\$ 3,130,752
COST OF SALES	1,191,493	1,103,185
GROSS PROFIT	2,079,362	2,027,567
OPERATING EXPENSES:		
Sales and marketing	1,191,079	1,304,732
General and administrative	354,908	330,777
Research and development	286,551	325,028
Total operating expenses	1,832,538	1,960,537
OPERATING INCOME	246,824	67,030
Interest expense, net	(14,449)	(8,293)
Other income (expense), net	535	299
Interest and other income (expense), net	(13,914)	(7,994)
INCOME BEFORE PROVISION FOR INCOME TAXES	232,910	59,036
Provision for income taxes		
NET INCOME	\$ 232,910	\$ 59,036
Net income per share basic and diluted	\$ 0.04	\$ 0.01
Weighted average shares basic	6,455,100	6,447,100
Weighted average shares diluted	6,455,100	6,450,709

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents**Encision Inc.****Condensed Statements of Operations****(Unaudited)**

Nine Months Ended	December 31, 2008	December 31, 2007
NET SALES	\$ 9,711,029	\$ 8,882,413
COST OF SALES	3,714,908	3,300,591
GROSS PROFIT	5,996,121	5,581,822
OPERATING EXPENSES:		
Sales and marketing	3,887,030	3,755,460
General and administrative	1,079,861	1,053,022
Research and development	855,764	988,659
Total operating expenses	5,822,655	5,797,141
OPERATING INCOME (LOSS)	173,466	(215,319)
Interest expense, net	(50,073)	(23,292)
Other income (expense), net	20,500	10,125
Interest and other income (expense), net	(29,573)	(13,167)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	143,893	(228,486)
Provision for income taxes		
NET INCOME (LOSS)	\$ 143,893	\$ (228,486)
Net income (loss) per share basic and diluted	\$ 0.02	\$ (0.04)
Weighted average shares basic and diluted	6,453,338	6,439,527

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents**Encision Inc.****Condensed Statements of Cash Flows****(Unaudited)**

Nine Months Ended	December 31, 2008	December 31, 2007
Cash flows from operating activities:		
Net income (loss)	\$ 143,893	\$ (228,486)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Depreciation and amortization	181,102	151,443
Stock-based compensation expense related to stock options	124,259	111,554
Stock-based interest expense related to warrants	9,381	9,381
Provision for doubtful accounts, net	(1,000)	(5,000)
Provision for inventory obsolescence, net	(20,000)	(15,000)
Change in operating assets and liabilities:		
Accounts receivable	20,916	(48,430)
Inventories	192,816	(312,508)
Prepaid expenses and other assets	9,558	148,850
Accounts payable	136,209	73,668
Accrued compensation and other accrued liabilities	(187,469)	(43,054)
Net cash provided by (used in) operating activities	609,665	(157,582)
Cash flows from investing activities:		
Acquisition of property and equipment	(184,250)	(464,030)
Patent costs	(28,492)	(41,623)
Net cash (used in) investing activities	(212,742)	(505,653)
Cash flows from financing activities:		
(Paydown of) borrowings from credit facility	(407,058)	280,000
Proceeds from the exercise of stock options	11,520	45,740
Net cash (used in) provided by financing activities	(395,538)	325,740
Net increase (decrease) in cash and cash equivalents	1,385	(337,495)
Cash and cash equivalents, beginning of period	70,995	436,403
Cash and cash equivalents, end of period	\$ 72,380	\$ 98,908

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

ENCISION INC.

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

DECEMBER 31, 2008

(Unaudited)

(1) ORGANIZATION AND NATURE OF BUSINESS

Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM® surgical instrument technology is changing the marketplace for electrosurgical devices and instruments by providing a solution to a patient safety risk in laparoscopic surgery. Our sales to date have been made principally in the United States.

We have, except for the nine months ended December 31, 2008 and fiscal years 2004 and 2003 when we achieved profitable operations, incurred losses since our inception and have an accumulated deficit of \$16,314,713 at December 31, 2008. Operations have been financed primarily through issuances of our common stock. Our liquidity has substantially diminished because of such continuing operating losses, and we may be required to seek additional capital in the future.

Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals in the United States.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation. The condensed interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles accepted in the United States have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. The condensed interim financial statements and notes thereto should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-KSB for the fiscal year ended March 31, 2008, filed on June 28, 2008.

The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements set forth in Accounting Principles Board Opinion 28 and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with accounting principles generally

Edgar Filing: ENCISION INC - Form 10-Q

accepted in the United States. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year.

Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expense during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents. For purposes of reporting cash flows, we consider all cash and highly liquid investments with an original maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments. In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) 157, Fair Value Measurements , which is effective for fiscal years beginning after November 15, 2007 and for interim periods within those years. This statement defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements. This statement applies under other accounting pronouncements that require or permit fair value measurements. The statement indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. SFAS 157 defines fair value based upon an exit price model.

We adopted SFAS 157 as of April 1, 2008. Our financial instruments consist of cash and cash equivalents and short-term trade receivables and payables. The carrying values of cash and cash equivalents and short-term receivables and payables approximate their fair value due to their short maturities.

Concentration of Credit Risk. SFAS 105, Disclosure of Information About Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk, requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash. The amount of cash that we have on deposit with financial institutions may at any time exceed the \$250,000 federally insured limit at December 31, 2008. However, we believe that the financial institutions are financially sound and the risk of loss is minimal.

Financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying value of all financial instruments approximate fair value.

We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with two financial institutions in the form of demand deposits and money market funds.

Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful

Edgar Filing: ENCISION INC - Form 10-Q

Table of Contents

accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at December 31, 2008 of \$1,432,854 included no more than 8% from any one customer. The net accounts receivable balance at March 31, 2008 of \$1,452,770 included no more than 4% from any one customer.

Warranty Accrual. We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage incurred in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required.

Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or market. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At December 31, 2008 and March 31, 2008, inventory consisted of the following:

	December 31, 2008		March 31, 2008	
Raw materials	\$	1,125,710	\$	1,296,761
Finished goods		1,017,427		1,039,192
Total gross inventories		2,143,137		2,335,953
Less reserve for obsolescence		(45,000)		(65,000)
Total net inventories	\$	2,098,137	\$	2,270,953

Property and Equipment. Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. Prior to fiscal year 2008, we utilized the double-declining method of depreciation for property and equipment due to the expected usage of the property and equipment over time. This method is expected to continue throughout the life of this equipment. Manufacturing and production equipment acquired, but not placed in service, in fiscal year 2007 and manufacturing and production equipment acquired after fiscal year 2007 is of a different technology for which the straight-line method is more appropriate. Therefore, we used the straight-line method of depreciation for this and other property and equipment starting April 1, 2007. This difference in depreciation methods utilized for manufacturing and production equipment is based on the technological differences of the equipment and does not constitute a change in accounting principle. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized.

Long-Lived Assets. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. A long-lived asset is considered impaired when estimated future cash flows related to the asset, undiscounted and without interest, are insufficient to recover the carrying amount of the asset. If deemed impaired, the long-lived asset is reduced to its estimated fair value. Long-lived assets to be disposed of are reported at the lower of their carrying amount or estimated fair value less cost to sell.

Patents. The costs of applying for patents are capitalized and amortized on a straight-line basis over the lesser of the patent's economic or legal life (17 years in the United States). Capitalized costs are expensed if patents are not granted. We review the carrying value of our patents periodically to determine whether the patents have continuing value, and such reviews could result in the conclusion that the recorded amounts have been impaired; however, we have determined no impairment is necessary as of December 31, 2008.

Edgar Filing: ENCISION INC - Form 10-Q

Accrued Liabilities. We have accrued \$50,000 related to warranty claims, \$60,805 related to sales commissions and \$26,604 related to rent normalization and have included these amounts in accrued liabilities in the accompanying balance sheet at December 31, 2008. At March 31, 2008, we had accrued \$75,000 related to warranty claims, \$107,034 related to sales commissions and \$58,890 related to rent normalization and have included these amounts in accrued liabilities in the accompanying balance sheet at March 31, 2008.

Income Taxes. We account for income taxes under the provisions of SFAS 109, Accounting for Income Taxes (SFAS 109). SFAS 109 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. SFAS 109 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. During the three and nine months ended December 31, 2008, we reversed our deferred tax assets and valuation allowance by the effective tax rate on loss carryforwards that were used to offset taxable income for these periods. During fiscal year 2008, no tax benefit was obtained from our loss. As a result, no tax benefit is reflected in the accompanying statements of operations for fiscal year 2008. Should we achieve sufficient, sustained income in the future, we may conclude that more or all of the valuation allowance should be reversed. FASB Interpretation (FIN) No. 48, Accounting for Uncertainty in Income Taxes requires us to make many subjective assumptions and judgments regarding our income tax exposures. At December 31, 2008, we had no unrecognized tax benefits which would affect the effective tax rate if recognized and had no accrued interest or penalties related to uncertain tax positions.

Sales Recognition. Sales from product sales is recorded when we ship the product and title has passed to the customer, provided that we have evidence of a customer arrangement and can conclude that collection is probable. Our shipping policy is FOB Shipping Point. We recognize revenue from sales to stocking distributors when there is no right of return, other than for normal warranty claims. We have no ongoing obligations related to product sales, except for normal warranty.

Research and Development Expenses. We expense research and development costs for products and processes as incurred.

Stock-Based Compensation. Beginning in fiscal year 2007, we adopted SFAS 123 (revised 2004), Share-Based Payment (SFAS 123(R)), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values. SFAS 123(R) supersedes our previous accounting under Accounting Principles Board Opinion 25, Accounting for Stock Issued to Employees (APB 25), for periods beginning in fiscal year 2007. In March 2005, the Securities and

Edgar Filing: ENCISION INC - Form 10-Q

Table of Contents

Exchange Commission issued Staff Accounting Bulletin 107 (SAB 107) relating to SFAS 123(R). We have applied the provisions of SAB 107 in our adoption of SFAS 123(R).

We have adopted SFAS 123(R) using the modified prospective transition method, which requires the application of the accounting standard as of April 1, 2006, the first day of our fiscal year 2007. Our financial statements as of and for fiscal years 2008 and 2007 reflect the impact of SFAS 123(R). In accordance with the modified prospective transition method, our financial statements for prior periods have not been restated to reflect, and do not include, the impact of SFAS 123(R). Stock-based compensation expense recognized under SFAS 123(R) for the three and nine months ended December 31, 2008 was \$45,828 and \$124,259, respectively, which consisted of stock-based compensation expense related to grants of employee stock options. Stock-based compensation expense related to employee stock options during the three and nine months ended December 31, 2007 was \$36,340 and \$111,554, respectively.

SFAS 123(R) requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statement of operations. Prior to the adoption of SFAS 123(R), we accounted for stock-based awards to employees and directors using the intrinsic value method in accordance with APB 25 as allowed under SFAS 123, Accounting for Stock-Based Compensation (SFAS 123). Under the intrinsic value method, no stock-based compensation expense had been recognized in our statement of operations because the exercise price of our stock options granted to employees and directors equaled the fair market value of the underlying stock at the date of grant.

Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statement of operations for the three months ended December 31, 2008 and 2007 included compensation expense for share-based payment awards granted prior to, but not yet vested as of December 31, 2008, based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123 and compensation expense for the share-based payment awards granted subsequent to July 30, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS 123(R). Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statements of operations for the three months ended December 31, 2008 and 2007 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. SFAS 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Upon adoption of SFAS 123(R), we continued to use the Black-Scholes option-pricing model (Black-Scholes model), which was previously used for our pro forma information required under SFAS 123. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with SFAS 123(R) and SAB 107 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.

On November 10, 2005, FASB issued FASB Staff Position FAS 123(R)-3, Transition Election Related to Accounting for Tax Effects of Share-Based Payment Awards. We have elected to adopt the alternative transition method provided in the FASB Staff Position for calculating the tax effects of stock-based compensation pursuant to SFAS 123(R). The alternative transition method includes simplified methods to establish the beginning balance of the additional paid-in capital pool (APIC pool) related to the tax effects of employee stock-based compensation and to determine the subsequent impact on the APIC pool and statements of cash flows of the tax effects of employee stock-based compensation awards that are outstanding upon adoption of SFAS 123(R).

Segment Reporting. We have concluded that we have one operating segment.

(3) BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE

Net income or loss per share is calculated in accordance with SFAS 128, Earnings Per Share (SFAS 128). Under the provisions of SFAS 128, basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income or loss per common share is computed by dividing the net income or loss for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options to purchase shares where the exercise price was greater than the average market price of common shares for the period. As a result of our net loss for the nine months ended December 31, 2007, all potentially dilutive securities in the loss year would be anti-dilutive and were excluded from the computation of diluted loss per share, and there are no differences between basic and diluted per share amounts for the loss year presented.

The following table presents the calculation of basic and diluted net loss per share:

	Three Months Ended		Nine Months Ended	
	December 31, 2008	December 31, 2007	December 31, 2008	December 31, 2007
Net income (loss)	\$ 232,910	\$ 59,036	\$ 143,893	\$ (228,486)
Weighted-average shares basic	6,455,100	6,447,100	6,453,338	6,439,527
Effect of dilutive potential common shares		3,609		
Weighted-average shares diluted	6,455,100	6,450,709	6,453,338	6,439,527
Net income (loss) per share basic	\$ 0.04	\$ 0.01	\$ 0.02	\$ (0.04)
Net income (loss) per share diluted	\$ 0.04	\$ 0.01	\$ 0.02	\$ (0.04)
Antidilutive employee stock options	590,000	381,391	590,000	385,000

Table of Contents

(4) COMMITMENTS AND CONTINGENCIES

We currently lease our facilities at 6797 Winchester Circle, Boulder, Colorado under noncancelable lease agreements through August 14, 2009. The minimum future lease payment by fiscal year as of December 31, 2008 is as follows:

Fiscal Year	Amount
2009 (three months remaining)	\$ 62,423
2010	94,804
Total	\$ 157,227

Our minimum future equipment lease payments with General Electric Capital Corporation as of December 31, 2008, by fiscal year, are as follows:

Fiscal Year	Amount
2009 (three months remaining)	\$ 25,469
2010	101,873
2011	101,873
2012	101,873
2013	101,873
2014	8,488
Total	\$ 441,449

We are subject to regulation by the United States Food and Drug Administration (FDA). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine compliance with these regulations. We believe that we were in substantial compliance with all known regulations as of December 31, 2008. FDA inspections are conducted periodically at the discretion of the FDA. Our latest inspection by the FDA occurred in May 2004.

On November 10, 2006, we entered into a credit facility agreement with Silicon Valley Bank. The terms of the credit facility include a line of credit for \$2,000,000 for three years at an interest rate calculated at prime rate plus 1.25%, subject to increase upon a default. In connection with the credit facility, we issued warrants to Silicon Valley Bank to purchase 28,000 shares of our common stock at a per share price of \$2.75. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. As of December 31, 2008, we had borrowed \$198,942 from the credit facility and, under our eligible receivables and inventory limit, had an additional \$1,507,068 available to borrow.

(5) VALUATION AND EXPENSE INFORMATION UNDER SFAS 123(R)

Edgar Filing: ENCISION INC - Form 10-Q

On April 1, 2006, we adopted SFAS 123(R), which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors, including employee stock options, based on estimated fair values. The following table summarizes stock-based compensation expense related to employee stock options and employee stock purchases under SFAS 123(R) for the three and nine months ended December 31, 2008 and 2007, which was allocated as follows:

	Three Months Ended		Nine Months Ended	
	December 31, 2008	December 31, 2007	December 31, 2008	December 31, 2007
Cost of sales	\$ 1,113	\$	\$ 1,533	\$
Sales and marketing	7,950	7,051	22,068	24,046
General and administrative	30,756	24,806	85,007	74,418
Research and development	6,009	4,483	15,651	13,090
Stock-based compensation expense	\$ 45,828	\$ 36,340	\$ 124,259	\$ 111,554

The Black-Scholes model requires the use of actual employee exercise behavior data and the application of a number of assumptions, including expected volatility, risk-free interest rate and expected dividends. Employee stock options to purchase 160,000 and 200,000 shares of stock were granted during the three and nine months ended December 31, 2008, respectively. The weighted-average assumptions for employee stock options granted during the three and nine months ended December 31, 2008 are summarized as follows:

	Three Months Ended December 31, 2008	Nine Months Ended December 31, 2008
Risk-free interest rate	3.0%	3.0%
Expected life (in years)	5.0	5.0
Expected volatility	64%	60%
Expected dividend	0%	0%

As of December 31, 2008, \$279,000 of total unrecognized compensation costs related to nonvested stock is expected to be recognized over a weighted-average period of two years.

(6) RELATED PARTY TRANSACTION

We paid consulting fees of approximately \$13,000 and \$42,000 to an entity owned by one of our directors during the three and nine months ended December 31, 2008, respectively and approximately \$16,000 and \$47,000 during the three and nine months ended December 31, 2007, respectively.

Table of Contents

ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements contained in this section on Management's Discussion and Analysis are not historical facts, including statements about our strategies and expectations with respect to new and existing products, market demand, acceptance of new and existing products, marketing efforts, technologies and opportunities, market and industry segment growth, and return on investments in products and markets. These statements are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward looking statements. All forward looking statements in this section on Management's Discussion and Analysis are based on information available to us on the date of this document, and we assume no obligation to update such forward looking statements. Readers of this Form 10-Q are strongly encouraged to review the section entitled *Risk Factors* in our Form 10-KSB for the fiscal year ended March 31, 2008.

General

Encision Inc., a medical device company based in Boulder, Colorado, has developed and launched innovative technology that is emerging as a standard of care in minimally-invasive surgery. We believe that our patented AEM® Surgical Instruments are changing the marketplace for electro-surgical devices and laparoscopic instruments by providing a solution to a well documented patient safety risk in laparoscopic surgery.

We were founded to address market opportunities created by the increase in minimally-invasive surgery (MIS) and surgeons' preference for using electro-surgery devices in these procedures. The product opportunity was created by surgeons' continued widespread demand for using monopolar electro-surgery instruments, which, when used in laparoscopic surgery, are susceptible to causing inadvertent collateral tissue damage outside the surgeon's field of view. The risk of unintended electro-surgical burn injury to the patient in laparoscopic surgery has been well documented. This risk poses a threat to patient safety and creates liability exposure for surgeons and hospitals that do not adequately address the issue.

Our patented AEM technology provides surgeons with the desired tissue effects, while preventing stray electro-surgical energy that can cause unintended and unseen tissue injury. AEM Laparoscopic Instruments are equivalent to conventional instruments in functionality, but they incorporate active electrode monitoring technology to dynamically and continuously monitor the flow of electro-surgical current, thereby helping to prevent patient injury. With our shielded and monitored instruments, surgeons are able to perform electro-surgical procedures more safely and effectively than when using conventional instruments. In addition, our AEM instruments are cost competitive with conventional non-shielded, non-monitored instruments. The result is advanced patient safety at comparable cost and with no change in surgeon technique.

AEM technology has been recommended and endorsed by sources from various groups involved in minimally-invasive surgery. Surgeons, nurses, biomedical engineers, the medicolegal community, malpractice insurance carriers and electro-surgical device manufacturers advocate the use of AEM technology. Recommendations from the malpractice insurance and medicolegal communities complement the broad clinical endorsements AEM technology has garnered over the past few years.

Adding further credibility to the benefits of our AEM technology are our supplier agreements with Novation and Premier, two of the largest Group Purchasing Organizations (GPOs) in the United States. Together, Novation and Premier represent over 3,000 hospitals which perform

Edgar Filing: ENCISION INC - Form 10-Q

over 50% of all surgery in the U.S. We believe that these GPO supplier agreements give further indication that AEM technology is gaining broader acceptance in the market. We believe that having the nation's leading medical purchasing groups recognize the value of our technology reflects the potential impact that AEM products can have in the market and in advancing patient safety in surgery nationwide. These agreements do not involve purchase commitments, but we expect these relationships to expand the market visibility of AEM technology and to ease the procurement process for new hospital customers.

We have focused our marketing strategies to date on expanding the market awareness of the AEM technology and our broad independent endorsements and have continued efforts to improve and expand the AEM product line. Accordingly, we are currently focusing on modernizing our accepted AEM instruments to include ergonomics and user functionalities for which surgeons have been expressing a preference. During fiscal year 2006, we announced enTouch[®], an ergonomically-designed handle for our articulating instruments, and we plan to introduce new additions to the AEM product line in fiscal year 2009. During fiscal year 2009, we launched our next generation of enTouch handles for AEM articulating laparoscopic instrument inserts.

When a hospital changes to AEM technology, we receive recurring sales from sales of replacement instruments. We believe that there is no directly competing technology to supplant AEM products once a hospital switches to our products. The replacement market of reusable and disposable AEM products in hospitals that use our AEM technology represented over 90% of our sales during the three months ended December 31, 2008. This sales stream is expected to grow as the base of hospitals that switch to AEM technology continues to grow. In addition, we intend to develop disposable versions of more of our AEM products in order to meet market demands and expand our sales opportunities.

We have, except for the nine months ended December 31, 2008 and fiscal years 2004 and 2003 when we achieved profitable operations, incurred losses since our inception and have an accumulated deficit of \$16,314,713 at December 31, 2008. Operations have been financed primarily through issuances of our common stock. Our liquidity has substantially diminished because of such continuing operating losses, and we may be required to seek additional capital in the future.

During the nine months ended December 31, 2008, we provided \$609,665 of cash from our operations and used \$184,250 for investments in equipment. As of December 31, 2008, we had \$72,380 in cash and cash equivalents available to fund future operations, an increase of \$1,385 from March 31, 2008. As of December 31, 2008, we had borrowed \$198,942 from our \$2,000,000 credit facility, a decrease of \$407,058 from March 31, 2008. Our working capital was \$2,147,508 at December 31, 2008 compared to \$2,483,993 at March 31, 2008.

Historical Perspective

We were organized in 1991 and spent several years developing the AEM monitoring system and protective sheaths to adapt to conventional electrosurgical instruments. During this period, we conducted product trials and applied for patents with the United States Patent Office and international patent agencies. Patents were issued to us in 1994, 1996, 1997, 1998 and 2002.

Table of Contents

As we evolved, it became clear to us that our AEM technology needed to be integrated into the standard laparoscopic instrument design. As the development program proceeded, it also became apparent that the merging of electrical and mechanical engineering skills in the instrument development process for our patented, integrated electrosurgical instruments was a complex and difficult task. As a result, instruments with integrated AEM technology were not completed for several years. Prior to offering a full range of laparoscopic electrosurgical instrumentation, it was difficult for hospitals to commit to the AEM solution, as we did not have adequate comparable surgical instrument options to meet surgeons demands. As of fiscal year 2005, a sufficiently broad product line was available to provide hospital operating rooms with AEM instruments in most of the designs common for laparoscopic surgery.

The launch of an expanded line of AEM instruments was accomplished over the past three years. We are now turning our focus to developing next generation versions of our AEM instruments to better meet market demands, particularly the demand for improved ergonomics and simplified user functionalities. This strategy coincides with the independent endorsements of our AEM technology and the recommendations from the malpractice insurance and medicolegal communities.

Outlook

Installed Base of AEM Monitoring Equipment: We believe that sales of our installed base of AEM monitors will increase sales as the inherent risks associated with monopolar laparoscopic electrosurgery become more widely acknowledged and as we focus on increasing our sales efficiency. We expect that the replacement sales of electrosurgical instruments and accessories will also increase as additional hospitals adopt AEM technology. We anticipate that the efforts to improve the quality of sales representatives carrying the AEM product line, along with increased marketing efforts and the introduction of next generation products, may provide the basis for increased sales and profitable operations. However, these measures, or any others that we may adopt, may not result in either increased sales or profitable operations. Furthermore, most of our next generation products are in the early stages of development.

We believe that the unique performance of the AEM technology and our breadth of independent endorsements provide an opportunity for continued market share growth. In our view, market awareness and awareness of the clinical credibility of the AEM technology, as well as awareness of our endorsements, are continually improving, and we expect this awareness to benefit our sales efforts for the remainder of fiscal year 2009. Our objectives in the remainder of fiscal year 2009 are to maintain expense controls while optimizing sales execution in the field, to expand market awareness of the AEM technology and to maximize the number of additional hospital accounts switching to AEM instruments while retaining existing hospital customers. In addition, acceptance of AEM products depends on surgeons preference for our instruments, which depends on factors such as ergonomics and ease of use in addition to the technological advantage of AEM products. If surgeons prefer other instruments to our instruments, our business results will suffer.

Possibility of Operating Losses: We have, except for the nine months ended December 31, 2008 and fiscal years 2004 and 2003 when we achieved profitable operations, incurred losses since our inception and have an accumulated deficit of \$16,314,713 at December 31, 2008. Operations have been financed primarily through issuances of our common stock. We have made strides toward improving our operating results but due to the ongoing need to develop, optimize and train our direct sales managers and the independent sales representative network, the need to support the development of refinements to our product line, and the need to increase sustained sales to a level adequate to cover fixed and variable operating costs, we may continue to operate at a net loss. Sustained losses, or our inability to generate sufficient cash flow from operations to fund our obligations, may result in a need to raise additional capital.

Sales Growth: We expect to generate increased sales in the U.S. from sales to new hospital customers and from expanded sales in existing hospitals as our network of direct and independent sales representatives becomes more efficient. We believe that the visibility and credibility of

Edgar Filing: ENCISION INC - Form 10-Q

the independent clinical endorsements for AEM technology will contribute to new hospital accounts and increase sales in fiscal year 2009. We also expect that supplier agreements with Novation and Premier, which together represent over 3,000 U.S. hospitals, will expose more hospitals to the benefits of AEM technology and may stimulate new hospital accounts. We also expect to increase market share through promotional programs of placing our AEM monitors at no charge into hospitals that commit to standardize AEM instruments. However, all of these efforts to increase market share and grow sales will depend in part on our ability to expand the efficiency and effective coverage range of our direct and independent sales representatives.

We also have longer term initiatives in place to improve our prospects. We expect that development of next generation versions of our AEM products will better position our products in the marketplace and improve our retention rate at hospitals that have changed to AEM technology, enabling us to grow our sales. We may also explore overseas markets to assess opportunities for sales growth internationally. Finally, we intend to explore opportunities to capitalize on our proven AEM technology via licensing arrangements and strategic alliances. These efforts to generate additional sales and further the market penetration of our products are longer term in nature and may not materialize. Even if we are able to successfully develop next generation products or identify potential international markets or strategic partners, we may not be able to capitalize on these opportunities.

Gross Profit and Gross Margins: Gross profit and gross margins can be expected to fluctuate from quarter to quarter as a result of product sales mix and sales volume. Gross margins on products manufactured or assembled by us are expected to improve at higher levels of production and sales.

Manufacturing Equipment: We expect to increase gross profit and gross margins by manufacturing our scissor inserts internally. We began manufacturing our scissor inserts in the third quarter of fiscal year 2008.

Sales and Marketing Expenses: We continue our efforts to expand domestic and international distribution capability, and we believe that sales and marketing expenses will decrease as a percentage of net sales with increasing sales volume.

Research and Development Expenses: Research and development expenses are expected to decrease modestly but will support development of refinements to our AEM product line, which will further expand the instrument options for surgeons.

Table of Contents

Results of Operations

For the three months ended December 31, 2008 compared to the three months ended December 31, 2007.

Net sales. Net sales for the quarter ended December 31, 2008, were \$3,270,854 compared to \$3,130,752 for the quarter ended December 31, 2007, an increase of 4%. The increase is attributable to the addition of new hospital accounts, partially offset by business lost from hospitals that previously changed to AEM technology. We opened five new hospital accounts for AEM technology in the three months ended December 31, 2008 versus nine new hospital accounts for AEM technology in the three months ended December 31, 2007. We have changed and added new sales managers and independent sales representatives in an effort to capitalize on identified market opportunities. It will take a number of months before new sales managers and new independent sales representatives generate new hospital accounts, but we expect that the combination of these new additions will provide the focus that is needed to achieve market gains.

Gross profit. Gross profit for the quarter ended December 31, 2008 of \$2,079,362 represented an increase of 3% from gross profit of \$2,027,567 for the quarter ended December 31, 2007. Gross profit as a percentage of sales (gross margins) decreased from 65% for the quarter ended December 31, 2007 to 64% for the quarter ended December 31, 2008. The gross profit margin decrease for the quarter ended December 31, 2008 was primarily due to increased sales of lower gross profit margin products that was partially offset by a higher gross profit margin for our internally manufactured disposable scissor inserts. In the quarter ended December 31, 2008, gross profit margin was 0.8% higher as a result of a decrease in warranty claims.

Sales and marketing expenses. Sales and marketing expenses of \$1,191,079 for the quarter ended December 31, 2008 represented a decrease of 9% from sales and marketing expenses of \$1,304,732 for the quarter ended December 31, 2007. The decrease was a result of decreased commissions for independent sales representatives and decreased independent contractor and trade shows expenses. The decrease in such cost was partially offset by increased compensation for additional sales employees.

General and administrative expenses. General and administrative expenses of \$354,908 for the quarter ended December 31, 2008 represented an increase of 7% from general and administrative expenses of \$330,777 for the quarter ended December 31, 2007. The increase was the result of an increase to compensation.

Research and development expenses. Research and development expenses of \$286,551 for the quarter ended December 31, 2008 represented a decrease of 12% compared to \$325,028 for the quarter ended December 31, 2007. The decrease was a result of decreased compensation and outside services.

Net income. Net income was \$232,910 for the quarter ended December 31, 2008 compared to net income of \$59,036 for the quarter ended December 31, 2007. Net income increase was a result of increased sales income and reduced operating expenses.

The results of operations for the three months ended December 31, 2008 should not be taken as an indication of the results of operations for all or any part of the balance of the fiscal year.

Edgar Filing: ENCISION INC - Form 10-Q

For the nine months ended December 31, 2008 compared to the nine months ended December 31, 2007.

Net sales. Net sales for the nine months ended December 31, 2008, were \$9,711,029 compared to \$8,882,413 for the nine months ended December 31, 2007, an increase of 9%. The increase is attributable to the addition of new hospital accounts, partially offset by business lost from hospitals that previously changed to AEM technology. We opened thirty-four new hospital accounts for AEM technology in the nine months ended December 31, 2008 versus thirty new hospital accounts for AEM technology in the nine months ended December 31, 2007. We have changed and added new sales managers and independent sales representatives in an effort to capitalize on identified market opportunities. It will take a number of months before new sales managers and new independent sales representatives generate new hospital accounts, but we expect that the combination of these new additions will provide the focus that is needed to achieve market gains.

Gross profit. Gross profit for the nine months ended December 31, 2008 of \$5,996,121 represented an increase of 7% from gross profit of \$5,581,822 for the nine months ended December 31, 2007. Gross profit as a percentage of sales (gross margins) decreased from 63% for the nine months ended December 31, 2007 to 62% for the nine months ended December 31, 2008. The gross profit margin decrease for the nine months ended December 31, 2008 was primarily due to increased sales of lower gross profit margin products. The decrease was partially offset by a higher gross profit margin for our internally manufactured disposable scissor inserts.

Sales and marketing expenses. Sales and marketing expenses of \$3,887,030 for the nine months ended December 31, 2008 represented an increase of 4% from sales and marketing expenses of \$3,755,460 for the nine months ended December 31, 2007. The increase was a result of increased compensation for additional sales employees and increases in travel expenses and outside services. The increase in such cost was partially offset by decreased commissions for independent sales representatives and trade shows.

General and administrative expenses. General and administrative expenses of \$1,079,861 for the nine months ended December 31, 2008 represented a 3% increase from general and administrative expenses of \$1,053,022 for the nine months ended December 31, 2007. The increase was primarily the result of an increase to compensation. The increase in such cost was partially offset by reduced investor relations costs.

Research and development expenses. Research and development expenses of \$855,764 for the nine months ended December 31, 2008 represented a decrease of 13% compared to \$988,659 for the nine months ended December 31, 2007. The decrease was a result of decreased compensation, outside services and inventory usage.

Net income. Net income was \$143,893 for the nine months ended December 31, 2008 compared to a net loss of \$228,486 for the nine months ended December 31, 2007. Net income increase was a result of increased sales income that was partially reduced by increased operating expenses.

The results of operations for the nine months ended December 31, 2008 should not be taken as an indication of the results of operations for all or any part of the balance of the fiscal year.

Table of Contents

Liquidity and Capital Resources

To date, operating funds have been provided primarily by issuances of our common stock and warrants to purchase our common stock, which together totaled \$19,523,110 through December 31, 2008, and, to a lesser degree, by funds provided by sales of our products.

On November 10, 2006, we entered into a credit facility agreement with Silicon Valley Bank. The terms of the credit facility include a line of credit for \$2,000,000 for three years at an interest rate calculated at prime rate plus 1.25%, subject to increase upon a default. In connection with the credit facility, we issued warrants to Silicon Valley Bank to purchase 28,000 shares of our common stock at a per share price of \$2.75. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. As of December 31, 2008, we had borrowed \$198,942 from the credit facility and, under our eligible receivables and inventory limit, had an additional \$1,507,068 available to borrow.

Our operations provided \$609,665 of cash in the nine months ended December 31, 2008 on net sales of \$9,711,029. Cash was provided principally by sales and our reduced cost structure as it relates to engineering projects. The amounts of cash provided by and used in operations for the nine months ended December 31, 2008 are not indicative of the expected cash to be generated from or used in operations in fiscal year 2009. During the nine months ended December 31, 2008, we invested \$184,250 in the acquisition of property and equipment. As of December 31, 2008, we had \$72,380 in cash and cash equivalents available to fund future operations and have borrowed \$198,942 from our credit facility. Working capital was \$2,147,508 at December 31, 2008 compared to \$2,483,993 at March 31, 2008. Current liabilities were \$1,557,432 at December 31, 2008, compared to \$1,409,750 at March 31, 2008. The increase in current liabilities at December 31, 2008 was caused principally by a shift in debt from long-term debt to current liability line of credit.

If we are not successful in obtaining profitability and positive cash flow, additional capital may be required to maintain ongoing operations. We have explored and are continuing to explore options to provide additional financing to fund future operations as well as other possible courses of action. Such actions include, but are not limited to, securing further lines of credit, sales of debt or equity securities (which may result in dilution to existing shareholders), licensing of technology, strategic alliances and other similar actions. There can be no assurance that we will be able to obtain additional funding (if needed), on acceptable terms or at all, through a sale of our common stock, loans from financial institutions or other third parties, or any of the actions discussed above. If we cannot sustain profitable operations, and additional capital is unavailable, lack of liquidity could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

We currently lease our facilities at 6797 Winchester Circle, Boulder, Colorado under noncancelable lease agreements through August 14, 2009. The minimum future lease payment by fiscal year as of December 31, 2008 is as follows:

Fiscal Year	Amount
2009 (three months remaining)	\$ 62,423
2010	94,804
Total	\$ 157,227

Our minimum future equipment lease payments with General Electric Capital Corporation as of December 31, 2008, by fiscal year, are as follows:

Edgar Filing: ENCISION INC - Form 10-Q

Fiscal Year	Amount
2009 (three months remaining)	\$ 25,469
2010	101,873
2011	101,873
2012	101,873
2013	101,873
2014	8,488
Total	\$ 441,449

Our fiscal year 2009 operating plan is focused on increasing new hospital accounts, retaining existing hospital customers, growing sales, increasing gross profits and conserving cash. We are investing in research and development efforts to develop next generation versions of the AEM product line. We have invested in manufacturing property and equipment to manufacture disposable scissors inserts internally and reduce our cost of sales. We cannot predict with certainty the expected sales, gross profit, net income or loss and usage of cash and cash equivalents for fiscal year 2009. However, we believe that our cash resources and credit facility will be sufficient to fund our operations for at least the next twelve months. If we are unable to manage our business operations in line with budget expectations, it could have a material adverse effect on our business viability, financial position, results of operations and cash flows. If we are not successful in achieving profitability and positive cash flow, additional capital may be required to maintain ongoing operations.

On December 5, 2008, the OTC Bulletin Board (OTCBB) initiated quotes of our stock with a trading symbol of ECIA.OB. The Company will continue to be a Securities and Exchange Commission (SEC) reporting company and believes that it is current in all of its required SEC and regulatory filings. We do not pay a listing fee to the OTCBB.

Income Taxes

As of March 31, 2008, net operating loss carryforwards totaling approximately \$16,400,000 are available to reduce taxable income in the future. The net operating loss carryforwards expire, if not previously utilized, at various dates beginning in the fiscal year ending March 31, 2009. We have not paid income taxes since our inception. The Tax Reform Act of 1986 and other income tax regulations contain provisions which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including changes in ownership interests. We have established a valuation allowance for the entire amount of our deferred tax asset since inception due to our history of losses. Should we achieve

Table of Contents

sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed. If some or all of the valuation allowance were reversed, then, to the extent of the reversal, a tax benefit would be recognized which would result in an increase to income.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, sales and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to bad debts, inventories, sales returns, warranty, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements.

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required, which would increase our expenses during the periods in which any such allowances were made. The amount recorded as a provision for bad debts in each period is based upon our assessment of the likelihood that we will be paid on our outstanding receivables, based on customer-specific as well as general considerations. To the extent that our estimates prove to be too high, and we ultimately collect a receivable previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, we have experienced some costs related to warranties. The warranty accrual is based on historical experience and is adjusted based on current experience. Should actual warranty experience differ from our estimates, revisions to the estimated warranty liability would be required.

We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based on assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. Any write-downs of inventory would reduce our reported net income during the period in which such write-downs were applied. To the extent that our estimates prove to be too high, and we ultimately utilize or sell inventory previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We recognize deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. Should we achieve sufficient, sustained income in the future, we may conclude that all or some of the valuation allowance should be reversed.

Edgar Filing: ENCISION INC - Form 10-Q

Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. Prior to fiscal year 2008, we utilized the double-declining method of depreciation for property and equipment due to the expected usage of the property and equipment over time. This method is expected to continue throughout the life of this equipment. Manufacturing and production equipment acquired, but not placed in service, in fiscal year 2007 and manufacturing and production equipment acquired after fiscal year 2007 is of a different technology for which the straight-line method is more appropriate. Therefore, we used the straight-line method of depreciation for this and other property and equipment starting April 1, 2007. This difference in depreciation methods utilized for manufacturing and production equipment is based on the technological differences of the equipment and does not constitute a change in accounting principle. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized.

We amortize our patent costs over their estimated useful lives, which is typically the remaining statutory life. From time to time, we may be required to adjust these useful lives of our patents based on advances in technology, competitor actions, and the like. We review the recorded amounts of patents at each period end to determine if their carrying amount is still recoverable based on our expectations regarding sales of related products. Such an assessment, in the future, may result in a conclusion that the assets are impaired, with a corresponding charge against earnings.

We currently estimate forfeitures for stock-based compensation expense related to employee stock options at 7% and evaluate the forfeiture rate quarterly. Other assumptions that are used in calculating stock-based compensation expense include risk-free interest rate, expected life, expected volatility and expected dividend.

Table of Contents

ITEM 4 – CONTROLS AND PROCEDURES

(a) We have carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Accounting and Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934 (the Exchange Act)). Based upon that evaluation, the Chief Executive Officer and the Principal Accounting and Financial Officer concluded that, as of December 31, 2008, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us under the Exchange Act was recorded, processed, summarized and reported within the time periods specified under the Exchange Act rules and forms.

(b) During the quarter ended December 31, 2008, there were no changes in our internal control over financial reporting or in other factors that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, nor were there any significant deficiencies or material weaknesses in such disclosure controls and procedures or internal control over financial reporting requiring corrective actions. As a result, no corrective actions were taken.

Table of Contents

PART II. **OTHER INFORMATION**

ITEM 6 **EXHIBITS**

The following exhibits are filed with this report on Form 10-Q or are incorporated by reference:

- 3.1 Articles of Incorporation of the Company, as amended (incorporated by reference from Registration Statement #333-4118-D dated June 25, 1996).

- 3.2 Bylaws of the Company (incorporated by reference from Current Report on Form 8-K dated October 30, 2007).

- 4.1 Form of certificate for shares of Common Stock (incorporated by reference from Registration Statement #333-4118-D dated June 25, 1996).

- 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Exchange Act (filed herewith).

- 31.2 Certification of Principal Financial and Accounting Officer under Rule 13a-14(a) of the Exchange Act (filed herewith).

- 32.1 Certification of Periodic Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

Table of Contents

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Encision Inc.

February 13, 2009
Date

/s/ Marcia McHaffie
Marcia McHaffie
Controller
Principal Accounting Officer &
Principal Financial Officer